TGA fines Switch Nutrition $79,200 over unlawful health advertising

The Therapeutic Goods Administration has fined Switch Nutrition Pty Ltd $79,200 for alleged unlawful advertising, placing Australia’s health marketing practices firmly in the spotlight.

The regulator issued four infringement notices after identifying advertising that allegedly used prohibited representations, including references to serious diseases or conditions. According to the TGA, these types of claims cannot be used in advertising without prior approval or permission.

The TGA stated that the advertising involved products containing Nicotinamide Mononucleotide (NMN) and Vitamin D3 (cholecalciferol). It also reinforced that promoting therapeutic goods for uses outside their approved indications, known as off-label advertising, is unlawful.

The regulator noted that the activity occurred across online channels, including company-controlled digital platforms. Advertising obligations apply broadly, covering websites, social media, and content shared through third parties such as influencers.

What this means for healthcare businesses

For healthcare leaders, the implications extend beyond a single enforcement action.

As clinics, supplement brands, and digital health businesses continue to invest in direct-to-consumer marketing, all promotional activity remains subject to the Therapeutic Goods Advertising Code. This includes how products are described, the conditions they are associated with, and the outcomes implied in public messaging.

References to serious conditions are particularly restricted under the Code. Without explicit approval, these claims may breach advertising rules.

This is especially relevant in high-growth segments such as supplements and preventive health, where demand is strong and messaging can move toward implied therapeutic outcomes.

From an operational perspective, the case highlights the need for alignment between clinical, regulatory, and marketing functions. Ensuring that claims are accurate and compliant is now a core requirement.

For healthcare organisations, the immediate priority is reviewing public-facing content, including references to serious diseases, alignment with approved indications, and oversight of third-party marketing.

The TGA’s action is a reminder that enforcement of advertising rules is active and ongoing.

In a regulated market like Australia, growth is no longer just about reach. It is about saying the right thing, in the right way, within the rules.

Source:
Therapeutic Goods Administration (TGA), TGA issues infringement notices for alleged unlawful advertising of therapeutic goods involving prohibited representations
https://www.tga.gov.au/news/media-releases/tga-issues-infringement-notices-alleged-unlawful-advertising-therapeutic-goods-involving-prohibited-representations